Mineralocorticoid receptor antagonists in XXXX with preserved ejection fraction (HFpEF).

@entity1 @entity712 @entity296 @entity3556 @entity5026 @entity14292 @entity2753 @entity247 @entity520 @entity951 @entity972 @entity1482 @entity4144
The role of @entity1482 and @entity14292 in @entity1 with @entity712 with preserved Ejection Fraction (HFpEF) is not well defined. Since a growing medical literature has suggested that mineralocorticoid receptor antagonists may be beneficial for @entity1 with HFpEF, this review gives an in-depth update on the role of @entity1482 and @entity14292 and their implications for therapy in the setting of HFpEF. Eleven clinical studies, including seven randomized trials, were reviewed. Two randomized controlled trials evaluated the effect of @entity14292 on different end-points, including 6minute walk distance (6MWD), cardiovascular mortality, non-fatal reinfarction, hospitalization for unstable @entity951 and @entity712 . @entity14292 did not affect either 6MWD or event-free survival rates in the overall study population in these two reports. The effects of @entity1482 on similar composite endpoints were evaluated in 7 studies in @entity1 with HFpEF. Compared to placebo, hospitalization for @entity712 was significantly lower in the @entity1482 group and @entity1482 was also shown to improve diastolic function and induced beneficial remodeling through a reduction in @entity296 . The safety profile of @entity1482 and @entity14292 has been assessed in two recent studies. Data showed that @entity14292 and @entity1482 are both associated with the occurrence of @entity247 , @entity5026 , and abnormal @entity3556 and in addition, they can increase natriuresis and cause renal retention of @entity972 ; furthermore, @entity14292 may cause @entity4144 and promote the onset of @entity520 or @entity2753 . In conclusion although the mineralocorticoid receptor antagonists @entity14292 and @entity1482 improve clinical outcomes in @entity1 with HFrEF, additional data will be necessary to better define their risk-benefit profile, especially for @entity14292 , in the treatment of HFpEF.
